Literature DB >> 8090602

The association between carcinoma of the tonsil and Epstein-Barr virus--a study using radiolabelled in situ hybridization.

J M Nicholls1, S Pittaluga, L P Chung, K C So.   

Abstract

We reviewed 30 cases of carcinoma of the tonsil and classified them as squamous cell carcinoma, non-keratinizing differentiated carcinoma and non-keratinizing undifferentiated carcinoma. Five cases of non-keratinizing undifferentiated carcinoma were identified, and these, together with 5 cases of squamous cell carcinoma, were studied for the presence of Epstein-Barr virus by in situ hybridization using early RNA (EBERs) as probes. All cases of squamous cell carcinoma were negative for EBER and only one of the 5 cases of non-keratinizing undifferentiated carcinoma was positive. As a positive control we used a case of a primary nasopharyngeal carcinoma with extension to the tonsil. Though the tonsil and nasopharynx share similar anatomical and immunological features, we conclude that in the majority of cases EBV is not demonstrable in tonsillar carcinomas.

Entities:  

Mesh:

Year:  1994        PMID: 8090602     DOI: 10.1080/00313029400169281

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  3 in total

1.  Presence of Epstein-Barr virus in lymphoepithelioma-like carcinoma of the middle ear.

Authors:  S Y Leung; S T Yuen; C M Ho; W K Kwong; L P Chung
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

2.  Detection of Epstein-Barr and Human Papilloma Viruses in the Middle Ear Squamous Cell Carcinoma.

Authors:  Agus Surono; Bambang Hariwiyanto; Edhie Samodra
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2016-05-07

3.  Epstein-Barr virus and human papillomavirus infections and genotype distribution in head and neck cancers.

Authors:  Zeyi Deng; Takayuki Uehara; Hiroyuki Maeda; Masahiro Hasegawa; Sen Matayoshi; Asanori Kiyuna; Shinya Agena; Xiaoli Pan; Chunlin Zhang; Yukashi Yamashita; Minqiang Xie; Mikio Suzuki
Journal:  PLoS One       Date:  2014-11-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.